Alexander Thomas Elford

X @AlexElford3 ATE and WB contributed equally. Contributors ATE, RP, AHA-A and BC contributed to the design of the study. ATE, JM and BC designed the REDCAP. JM, AD and VK emailed all patients. ATE, WB, AD, VK, JM, AHA-A, JS and BC were involved in recruitment. ATE and WB drafted the first version of the manuscript. All authors critically reviewed the manuscript for important intellectual content. All authors approved the final version of the manuscript. BC is the guarantor.

Discussion In this highly medically refractory cohort, where 82% of the cohort had exposure to at least two classes of advanced therapies, and 52% had exposure to at least three classes of advanced therapies, persistence rates were 81.7% at 24 weeks. Response to induction was 64% of patients achieving clinical remission, 55% achieving CRP remission and 50% achieving FCAL remission. Sustained remission occurred in a substantial proportion of patients.

Methods We conducted a multicentre retrospective cohort analysis involving five hospitals across two National Health Service (NHS) health organisations in the UK (NHS Lothian and Royal Devon University Healthcare NHS Foundation Trust). Data were retrospectively collected at each hospital by review of electronic medical records.